Probatebeta
Target

EPCAM

Epithelial cell adhesion molecule

As of the edition of 20 October 2026, EPCAM (epithelial cell adhesion molecule, UniProt P16422) has 13 drugs tested at it and 12 companies on the list, 3 on route A and 0 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P16422
How well studied
Biology documented; no tool compounds or approved drug yet
Where it sits in the cell
In more than one place
Solved structures
2
Disease areas
Cancer; Pregnancy and women's health; Urinary and reproductive; Digestive system; Hormones; Lungs and airways; Blood and lymph; Chemically induced
Registered trials of its drugs
38

Drugs at this target

StatusCount
Marketed1
Active5
Went quiet4
Stopped2
Status not established1
Total13
DrugStatusFurthest phaseUS protection
CatumaxomabMarketedPhase 3none listed
AdecatumumabActivePhase 2none listed
EdrecolomabStoppedPhase 3none listed
M701ActivePhase 3none listed
Oportuzumab monatoxStatus not establishedPhase 3none listed
Tucotuzumab celmoleukinWent quietPhase 2none listed
BA3182ActivePhase 1none listed
CX-2051ActivePhase 1none listed
Citatuzumab bogatoxStoppedPhase 1none listed
ING-1Went quietPhase 1none listed
KK2269ActivePhase 1none listed
MOC31-PEWent quietPhase 1none listed

12 of 13 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A3
Engaged6
Undetermined3
Total on the list12
Three companies on route A or B, with the route only
CompanyRoute
Merck KGaARoute A
Neovii BiotechRoute A
XomaRoute A

The other 9 companies at EPCAM

In the product

12 companies in all; 9 are not named here, and no score is.

See the 12 companies at EPCAM, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in cancer